Chemed Corp. CHE
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $2.5B | +65% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Operating income | $338.2M | -8% | FY ending Dec 31, 2025 |
| Net income | $265.2M | -12% | FY ending Dec 31, 2025 |
| Earnings per share | $18.34 | -8% | FY ending Dec 31, 2025 |
| Cash from operations | $388.3M | -7% | FY ending Dec 31, 2025 |
| Capital spending | $62.8M | +27% | FY ending Dec 31, 2025 |
| Share buybacks | $431.5M | +19% | FY ending Dec 31, 2025 |
| Dividends paid | $31.7M | +17% | FY ending Dec 31, 2025 |
| Cash | $74.5M | -58% | FY ending Dec 31, 2025 |
| Long-term debt | $92.5M | -50% | FY ending Dec 31, 2022 |
| Shareholders' equity | $979.4M | -12% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 13 sales ($8.8M) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Kevin J Mcnamarapresident and CEO, Director | Sold | 2,000 | $513.45 | $1.0M | Sep 28, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Sold | 2,000 | $501.40 | $1.0M | Sep 18, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Sold | 2,000 | $541.16 | $1.1M | Aug 21, 2026 |
| Spencer S Leeexecutive vice president | Sold | 1,000 | $541.04 | $541K | Aug 21, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Sold | 2,000 | $539.51 | $1.1M | Aug 3, 2026 |
| Patrick P GraceDirector | Sold | 190 | $532.00 | $101K | Jul 31, 2026 |
| Andrea R LindellDirector | Sold | 1,347 | $447.33 | $603K | Jun 9, 2026 |
| George J Iii WalshDirector | Sold | 500 | $437.83 | $219K | May 29, 2026 |
| Patrick P GraceDirector | Sold | 60 | $425.78 | $26K | May 8, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Sold | 2,000 | $421.13 | $842K | May 1, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Sold | 1,500 | $369.37 | $554K | Mar 27, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Sold | 2,000 | $403.18 | $806K | Mar 12, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Sold | 2,000 | $437.55 | $875K | Nov 24, 2025 |
Other insider moves (31): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Spencer S Leeexecutive vice president | Tax withholding | 11,160 | $508.93 | $5.7M | Sep 30, 2026 |
| Spencer S Leeexecutive vice president | Option exercise | 12,099 | $445.35 | $5.4M | Sep 30, 2026 |
| Thomas C Huttonvice president, Director | Tax withholding | 4,270 | $506.65 | $2.2M | Sep 28, 2026 |
| Thomas C Huttonvice president, Director | Option exercise | 4,629 | $445.35 | $2.1M | Sep 28, 2026 |
| Brian C JudkinsVP and Chief Legal Officer | Tax withholding | 5,878 | $548.96 | $3.2M | Aug 10, 2026 |
| Brian C JudkinsVP and Chief Legal Officer | Option exercise | 6,786 | $445.35 | $3.0M | Aug 10, 2026 |
| Joel L WherleyCEO - Vitas Healthcare | Tax withholding | 2,270 | $542.62 | $1.2M | Aug 5, 2026 |
| Joel L WherleyCEO - Vitas Healthcare | Option exercise | 2,599 | $445.35 | $1.2M | Aug 5, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Tax withholding | 19,802 | $529.22 | $10.5M | Jul 31, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Option exercise | 2,001 | $445.35 | $891K | Jul 31, 2026 |
| George J Iii WalshDirector | Award | 386 | $440.77 | $170K | May 18, 2026 |
| John Meredith Jr. MountDirector | Award | 386 | $440.77 | $170K | May 18, 2026 |
| Eileen P MccarthyDirector | Award | 386 | $440.77 | $170K | May 18, 2026 |
| Andrea R LindellDirector | Award | 386 | $440.77 | $170K | May 18, 2026 |
| Christopher J HeaneyDirector | Award | 386 | $440.77 | $170K | May 18, 2026 |
| Patrick P GraceDirector | Award | 386 | $440.77 | $170K | May 18, 2026 |
| Ron DelyonsDirector | Award | 386 | $440.77 | $170K | May 18, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Option exercise2 fills | 2,714 | $469.56 avg | $1.3M | Feb 13, 2026 |
| Kevin J Mcnamarapresident and CEO, Director | Tax withholding | 1,192 | $469.56 | $560K | Feb 13, 2026 |
| Spencer S Leeexecutive vice president | Option exercise2 fills | 499 | $469.56 avg | $234K | Feb 13, 2026 |
| Michael D WitzemanVP & Chief Financial Officer | Option exercise2 fills | 413 | $469.56 avg | $194K | Feb 13, 2026 |
| Brian C JudkinsVP and Chief Legal Officer | Option exercise2 fills | 351 | $469.56 avg | $165K | Feb 13, 2026 |
| Joel L WherleyCEO - Vitas Healthcare | Option exercise2 fills | 273 | $469.56 avg | $128K | Feb 13, 2026 |
| Thomas C Huttonvice president, Director | Option exercise2 fills | 199 | $469.56 avg | $93K | Feb 13, 2026 |
| Spencer S Leeexecutive vice president | Tax withholding | 154 | $469.56 | $72K | Feb 13, 2026 |
| Michael D WitzemanVP & Chief Financial Officer | Tax withholding | 120 | $469.56 | $56K | Feb 13, 2026 |
| Brian C JudkinsVP and Chief Legal Officer | Tax withholding | 102 | $469.56 | $48K | Feb 13, 2026 |
| Joel L WherleyCEO - Vitas Healthcare | Tax withholding | 80 | $469.56 | $38K | Feb 13, 2026 |
| Thomas C Huttonvice president, Director | Tax withholding | 72 | $469.56 | $34K | Feb 13, 2026 |
| Andrea R LindellDirector | Gift | 463 | – | – | Dec 26, 2025 |
| Spencer S Leeexecutive vice president | Gift | 60 | – | – | Nov 19, 2025 |
Trades by members of Congress
2 members reported 1 buy and 2 sales since Mar 6, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| Lisa C. McClain R | Bought | $1,001–$15K | Jun 24, 2025 | Aug 13, 202550 days later | Spouse |
| Byron Donalds R | Sold | $1,001–$15K | Mar 6, 2025 | Apr 14, 2025 | Spouse |
| Byron Donalds R | Sold | $1,001–$15K | Mar 6, 2025 | Apr 14, 2025 | Self |
Latest SEC filings
- News filing: Quarterly results 8-K · Oct 27, 2026
- Insider plans to sell 144 · Sep 28, 2026
- Insider plans to sell 144 · Sep 24, 2026
- Insider plans to sell 144 · Aug 21, 2026
- Insider plans to sell 144 · Aug 3, 2026
- Insider plans to sell 144 · Jul 31, 2026
- Quarterly report 10-Q · Jul 31, 2026
- News filing: Quarterly results 8-K · Jul 28, 2026
- News filing: Shareholder vote results 8-K · May 19, 2026
- Insider plans to sell 144 · May 8, 2026
- Insider plans to sell 144 · May 1, 2026
- Insider plans to sell 144 · May 1, 2026
- Quarterly report 10-Q · Apr 28, 2026
- News filing: Quarterly results 8-K · Apr 23, 2026
- News filing: Signed a major agreement, Took on new debt 8-K · Apr 13, 2026
- Shareholder meeting proxy DEF 14A · Apr 6, 2026
- Insider plans to sell 144 · Mar 27, 2026
- Insider plans to sell 144 · Mar 12, 2026
- Insider plans to sell 144 · Mar 12, 2026
- Annual report 10-K · Feb 27, 2026
- News filing: Quarterly results 8-K · Feb 25, 2026
- Insider plans to sell 144 · Dec 11, 2025
- Insider plans to sell 144 · Nov 24, 2025
- Quarterly report 10-Q · Oct 31, 2025
- News filing: Quarterly results 8-K · Oct 28, 2025
About Chemed Corp.
Business description
- Industry
- Services-Home Health Care Services
- Sector
- Industrial Applications and Services
- Headquarters
- Cincinnati, OH
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- NYSE
- Filer size
- Large accelerated filer
- Formerly
- ROTO-ROOTER INC
- SEC company number (CIK)
- 19584
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.